Conversion treatment With Sirolimus in renal transplant recipients

Shu-ming Ji,Ji-qiu Wen,Guo-zhu Sha,Dong-rui Cheng,Qi-quan Sun,Jin-Song Chen,Zhi-hong Liu,Lei-shi Li

DOI: https://doi.org/10.3969/j.issn.1673-8225.2009.31.003

2009-01-01

Abstract:BACKGROUND: Sirolimus is a new generation of immunosuppressive agent with little renal toxicity, as well as effects of anti-proliferation and anti-tumor, which can decrease the occurrence of adverse reaction such as hepatic and renal toxicity, as well as serious infection in renal transplant recipients. OBJECTIVE: To verify the efficacy and safety of conversion treatment with sirolimus in renal transplant recipients using the calcineurin inhibitor (CNI) with one or more risk factors. DESIGN, TIME AND SETTING: A retrospective analysis on cases was performed in the Research Institute of Nephrology, Nanjing General Hospital of Nanjing Military Command from June 2003 to December 2006. PARTICIPANTS: A total of 93 patients performed conversion treatment with sirolimus after renal transplantation. They consisted of 59 males and 34 females, with an average age of (38.2±11.1) years. Among them, CNI induced renal toxicity were in 13 (13.9%) cases, CNI induced hepatic toxicity were in 26 (28.0%) cases, post-transplantation diabetes mellitus were in 11 (11.8%) cases, chronic allograft nephropathy were in 33 (35.5%) cases, and post-transplantation tumor were in 10 (10.8%) cases. METHODS: Rapid conversion with sirolimus was performed in all patients. The CNI withdrawal was in 2 weeks. At 4 hours after oral administration of cyclosporin A or Tacrolimus, the patients took sirolimus. Initial dose of sirolimus was 6 mg, and repeated maintenance dose is 1.0-2.0 mg/d. The first concentration of sirolimus was detected at 5-7 days after first oral administration, and the target concentration was 6-10 μg/L. MAIN OUTCOME MEASURES: Serum creatinine levels, incidence of acute rejection, loss rate of grafts, pulmonary infection, and mortality rates were dynamically observed after conversion with sirolimus. RESULTS: The symptoms were markedly improved in patients with CNI induced renal toxicity and CNI induced liver toxicity, and the concentration of sirolimus were maintained at (5.1±1.2) μg/L. Serum creatinine levels decreased from (297.72±150.28) μmol/L to (123.76±44.2) μmol/L, and the liver function were recovery in 24 (92.3%) patients. 9 patients with high glucose returned to normal, and 2 patients were improved. Serum creatinine levels decreased more than 25% of primary level in 17 patients, and the effective rate was 51.5%. 10 patients with tumor were appeared 6-43 months after renal transplantation, no recurrence was found in 8 of them and 2 patients were dead. Acute rejections were occurred in 3 patients at 6 months after conversion treatment. The complications were included hyperlipidemia and proteinuria. 3 patients were dead, 6 patients returned to dialysis treatment, and 2 patients were removal of grafts. At 3 years after conversion treatment, the survival rates of patients and grafts were 90.9% and 75.8%, respectively. CONCLUSION: The conversion treatment with SRL and MMF may be a better option for the renal transplant recipients using the CNI with risk factors appeared.